Fed Circuit split decision denies Biogen’s bid to revive MS drug patent
02-12-2021
Australian court affirms Mylan patent invalidation
06-07-2020
Mylan scores multiple sclerosis patent win over Biogen
23-06-2020
ricochet64 / Shutterstock.com
Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera (dimethyl fumarate) yesterday, August 19.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Mylan, Biogen, Tecfidera, patent, dimethyl fumarate, multiple sclerosis, MS, generics, FDA
